- Home
- HLN vs CANF Comparison
HLN vs CANF Comparison
Compare HLN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLN
- CANF
- Stock Information
- Founded
- HLN 2022
- CANF 1994
- Country
- HLN United Kingdom
- CANF Israel
- Employees
- HLN N/A
- CANF N/A
- Industry
- HLN Package Goods/Cosmetics
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- HLN Consumer Discretionary
- CANF Health Care
- Exchange
- HLN Nasdaq
- CANF Nasdaq
- Market Cap
- HLN 45.6B
- CANF 7.9M
- IPO Year
- HLN N/A
- CANF N/A
- Fundamental
- Price
- HLN $10.22
- CANF $1.20
- Analyst Decision
- HLN Buy
- CANF Strong Buy
- Analyst Count
- HLN 1
- CANF 2
- Target Price
- HLN $10.95
- CANF $14.00
- AVG Volume (30 Days)
- HLN 13.6M
- CANF 413.8K
- Earning Date
- HLN 02-27-2025
- CANF 04-29-2025
- Dividend Yield
- HLN 1.65%
- CANF N/A
- EPS Growth
- HLN 38.94
- CANF N/A
- EPS
- HLN 0.20
- CANF N/A
- Revenue
- HLN $14,062,871,660.00
- CANF $674,000.00
- Revenue This Year
- HLN $5.66
- CANF $461.72
- Revenue Next Year
- HLN $4.86
- CANF N/A
- P/E Ratio
- HLN $25.21
- CANF N/A
- Revenue Growth
- HLN N/A
- CANF N/A
- 52 Week Low
- HLN $8.06
- CANF $1.22
- 52 Week High
- HLN $10.80
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- HLN 54.81
- CANF 37.12
- Support Level
- HLN $9.18
- CANF $1.22
- Resistance Level
- HLN $9.74
- CANF $1.82
- Average True Range (ATR)
- HLN 0.25
- CANF 0.13
- MACD
- HLN 0.03
- CANF -0.02
- Stochastic Oscillator
- HLN 74.55
- CANF 3.13
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).